MichaelStuartLeapmanMD

Urology • New Haven, CT

Surgical Oncology

Physician

Join to view full profile

Dr. Leapman is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Leapman's full profile

Already have an account?

Office
800 Howard Avenue
Yale Physicians Building
New Haven, CT 06519

Education & Training

University of California (San Francisco)Fellowship, Minimally Invasive Urologic Surgery, 2014 - 2016
Icahn School of Medicine at Mount SinaiResidency, Urology, 2010 - 2014
Icahn School of Medicine at Mount SinaiInternship, Transitional Year, 2009 - 2010
University of Maryland School of MedicineClass of 2009

Certifications & Licensure

CT State Medical License 2016 - 2025
NY State Medical License 2011 - 2015
American Board of Urology Urology

Publications & Presentations

PubMed

The Association Between Medical Insurance, Access to Care, and Outcomes for Patients with Uveal Melanoma in the United States.
Victoria A Marks, Basil K Williams Jr, Michael S Leapman, Carol L Shields
Seminars in Ophthalmology. 2025-04-01
Risks of grade reclassification among patients with Gleason grade group 1 prostate cancer and PI-RADS 5 findings on prostate MRI.
Vinaik Mootha Sundaresan, Lindsey Webb, Maximilian Rabil, Aleksandra Golos, Ryan Sutherland
Urologic Oncology. 2025-03-01
Feasibility of Pay for Performance and Transparency Interventions on the Selection and Quality of Observational Management for Patients With Low-Risk Prostate Cancer i...
Franklin D Gaylis, Michael S Leapman, Shellie D Ellis, Steven Hu, Matthew R Cooperberg
Urology Practice. 2025-03-01

Journal Articles

Regional Adoption of Commercial Gene Expression Testing for Prostate Cancer
Michael Leapman, MD, JAMA Oncology

Lectures

Real-world practice patterns and impact of PD-L1 expression testing in patients with advanced non-small cell lung cancer.
2019 ASCO Annual Meeting - 6/1/2019

Press Mentions

How to Avoid Overtreatment of Prostate CancerJanuary 15th, 2025
PSMA-PET Detects Hidden Metastasis in Recurrent Prostate CancerJanuary 8th, 2025
More Patients Opting for Close Monitoring of Early Stage Prostate CancerNovember 22nd, 2024
Join now to see all

Grant Support

Optimizing prostate cancer care: integrating risks, benefits, and patient experiences in the new era of molecular imagingYALE UNIVERSITY2023–2028